Innovative therapeutics

Investors/
Media

Welcome to BioMarin’s Investor Relations & Media Page

We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company.

BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly.

Recent News
Oct 9, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...

Oct 7, 2019

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich BioMarin's pipeline, which drives...

Oct 1, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a fireside discussion at the...

Events & Presentations

Stock Quote
NASDAQBMRN
BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information